ASTRIS real world study of osimertinib in patients (pts) with EGFR T790M NSCLC: Efficacy analysis by tissue or plasma T790M test

被引：0
|
作者：
Freitas, H. C. [1 ]
Park, K. [2 ]
Kim, D-W. [3 ]
Tiseo, M. [4 ]
Hochmair, M. J. [5 ,6 ]
Chang, G-C. [7 ]
Shi, Y-K. [8 ,9 ]
Moran, T. [10 ]
Chen, Y. [11 ]
Laskin, J. [12 ]
Solomon, B. [13 ]
Miranda, M. [14 ]
Rigas, J. [15 ]
Cheema, P. K. [16 ]
Kim, S-W. [17 ]
机构：
[1] AC Camargo Canc Ctr, Clin Res Unit, Sao Paulo, Brazil
[2] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Div Heamatol Oncol,Med, Seoul, South Korea
[3] Seoul Natl Univ Hosp, Dept Internal Med, Hematooncol, Seoul, South Korea
[4] Univ Hosp Parma, Med Oncol Unit, Parma, Italy
[5] Otto Wagner Hosp, Dept Resp & Crit Care Med, Resp Oncol Unit, Vienna, Austria
[6] Otto Wagner Hosp, Ludwig Boltzmann Inst COPD, Vienna, Austria
[7] Taichung Vet Gen Hosp, Dept Internal Med, Div Chest Med, Taichung, Taiwan
[8] Chinese Acad Med Sci, Natl Canc Ctr, Beijing Key Lab Clin Study Anticanc Mol Targeted, Dept Med Oncol, Beijing, Peoples R China
[9] Peking Union Med Coll, Beijing, Peoples R China
[10] ICO Badalona Hosp Germans Trias & Pujol, Med Oncol Serv, Barcelona, Spain
[11] Taipei Vet Gen Hosp, Dept Chest Med, Taipei, Taiwan
[12] British Columbia Canc Agcy, Dept Med Oncol, Vancouver, BC, Canada
[13] Peter MacCallum Canc Ctr, Dept Med Oncol, Melbourne, Vic, Australia
[14] AstraZeneca, Biometr & Informat Sci, Cambridge, England
[15] AstraZeneca, GMA Oncol TA, Gaithersburg, MD USA
[16] Univ Toronto, William Osler Hlth Syst, Med Oncol, Brampton, ON, Canada
[17] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, Seoul, South Korea
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
466O
引用
收藏
页码：149 / 149
页数：1
相关论文
共 50 条
  • [1] ASTRIS: A Real World Study of Osimertinib Treatment in Patients with EGFR T790M Positive Advanced NSCLC; Interim Analysis
    Kim, S.
    Cho, B. C.
    Kim, D.
    Park, K.
    Tiseo, M.
    Migliorino, M. R.
    Santo, A.
    Lee, J.
    Vicente, D.
    Paredes, A.
    O'Hanrahan, E.
    Freitas, H.
    Provencio, M.
    Chen, Y.
    Cheema, P.
    Milner, A.
    Rigas, J.
    Wu, Y.
    De Marinis, F.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2202 - S2202
  • [2] Osimertinib in EGFR T790M Advanced NSCLC: Analysis of Uncommon/Complex EGFR Mutations in a Real-World Study (ASTRIS)
    Cheema, P.
    Passaro, A.
    Martin, C.
    Tiseo, M.
    Park, K.
    Chang, G.
    Hu, Y.
    Cho, B. C.
    Miranda, M.
    Fernandes, A.
    Freitas, H.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S854 - S854
  • [3] ASTRIS: A real world treatment study of osimertinib in patients (pts) with EGFR T790M positive non-small cell lung cancer (NSCLC).
    De Marinis, Filippo
    Cho, Byoung Chul
    Kim, Dong-Wan
    Kim, Sang-We
    Hochmair, Maximilian J.
    Metro, Giulio
    Vansteenkiste, Johan F.
    Vicente, David
    Solomon, Benjamin J.
    Cheema, Parneet K.
    Freitas, Helano C.
    Provencio, Mariano
    Chen, Yuh-Min
    Wu, Yi-Long
    Milner, Alvin
    Rigas, James R.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [4] Loss of T790M Mutation is Associated with Early Progression to Osimertinib in Chinese Advanced NSCLC Patients Harboring EGFR T790M
    Zhao, S.
    Jiang, T.
    Li, X.
    Zhao, C.
    Su, C.
    Ren, S.
    Zhou, C.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S410 - S410
  • [5] ASTRIS global real world study of osimertinib in patients (pts) with EGFR T790M non-small cell lung cancer (NSCLC): Subpopulation analyses
    Provencio, M.
    Cheema, P. K.
    Vansteenkiste, J. F.
    Cho, B. C.
    Zhou, C.
    Yu, J.
    Martin, C.
    Park, K.
    He, Y.
    Hu, Y.
    Vicente, D.
    Miranda, M.
    Rigas, J.
    de Marinis, F.
    ANNALS OF ONCOLOGY, 2018, 29
  • [6] A phase II study to assess the efficacy of osimertinib in patients with EGFR MT(+)T790M(-) NSCLC
    Hayakawa, Daisuke
    Takeda, Masayuki
    Shimokawa, Mototsugu
    Nakamura, Atsushi
    Nosaki, Kaname
    Watanabe, Yasutaka
    Kato, Terufumi
    Tanaka, Hiroshi
    Takahashi, Toshiaki
    Oki, Masahide
    Tachihara, Motoko
    Fujimoto, Daichi
    Yamaguchi, Kakuhiro
    Hayashi, Hidetoshi
    Yamamoto, Shoichiro
    Iwama, Eiji
    Azuma, Koichi
    Yamamoto, Nobuyuki
    Nakagawa, Kazuhiko
    ANNALS OF ONCOLOGY, 2023, 34 : S1387 - S1387
  • [7] Loss of T790M mutation is associated with early progression to osimertinib in Chinese patients with advanced NSCLC who are harboring EGFR T790M
    Zhao, Sha
    Li, Xuefei
    Zhao, Chao
    Jiang, Tao
    Jia, Yijun
    Shi, Jinpeng
    He, Yayi
    Li, Jiayu
    Zhou, Fei
    Gao, Guanghui
    Li, Wei
    Chen, Xiaoxia
    Su, Chunxia
    Ren, Shengxiang
    Zhou, Caicun
    LUNG CANCER, 2019, 128 : 33 - 39
  • [8] ASTRIS a RWT with Osimertinib in NSCLC EGFR T790M Mutated: Disease Characteristics from Patients Included in Argentina
    Biolchi, M.
    Recondo, G.
    Casalnuovo, M.
    Tsou, F.
    Diaz Perez, I.
    Reinhold, F.
    Martin, C.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (09) : S169 - S169
  • [9] ASTRIS: A Real World Treatment Study of Osimertinib in Patients with EGFR T790M-Positive NSCLC
    Wu, Y.
    Cho, B. C.
    Zhou, Q.
    Chang, G.
    Jiang, L.
    Metro, G.
    Martin, C.
    De Castro, G.
    Vansteenkiste, J.
    Vicente, D.
    Milner, A.
    Rigas, J.
    Chen, Y.
    Provencio, M.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S358 - S359
  • [10] ASTRIS China: A Real-world Study of Osimertinib in Patients with EGFR T790M Positive Non-small-cell Lung Cancer (NSCLC)
    Zhou, Q.
    Zhang, H. -L.
    Jiang, L. -Y.
    Shi, Y. -K.
    Chen, Y.
    Yu, J. -M.
    Zhou, C. -C.
    He, Y.
    Hu, Y. -P.
    Liang, Z. -A.
    Pan, Y. -Y.
    Zhuo, W. -L.
    Song, Y.
    Wu, G.
    Chen, G. -Y.
    Lu, Y.
    Zhang, C. -Y.
    Zhang, C. -Y.
    Zhang, Y. -P.
    Chen, Y.
    Lu, S.
    Wu, Y. -L.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S429 - S430
12345